Manzo Pharmaceuticals Inc is engaged in developing affordable formulations for various drugs and supplement, focused on addressing the unmet medical needs of patients with patient-friendly and affordable solutions.
Website: | www.manzopharma.com/ |
Main Phone: | +1 570 249-6000 |
Address: | PO Box 107 |
Address 2: | Suite 305 |
State: | PA |
City / Town: | Milford |
Country: | USA |
Postal Code: | 18337 |
Exchange: | OTO |
NAICS: | Pharmaceutical P |
Last Price 0.0001 | Change $ 0. | Change % 0.00 | Tick N/A |
Bid N/A | Bid Size N/A | Ask N/A | Ask Size N/A |
Open N/A | High N/A | Low N/A | Prev Close 0.0001 |
Last Trade | Volume 0 | 52 Wk Hi 0.0055 | 52 Wk Low 0.0001 |
Market Cap 535 | Ex-Div Date N/A | Div Rate N/A | Yield N/A |
Shares 5,345,439.00 | EPS (TTM) 1.70 | PE Ratio 0.00 | Exchange CV EM |
Form Type | Form Description | Pages | Date |
---|---|---|---|
D | Official notice of an offering of securities that is made without registration under the Securities Act in reliance on an exemption provided by Regulation D and Section 4(6) under the Act | 1 | 2011-03-25 |
15-12G | Certification of termination of registration of a class of security under Section 12(g) or notice of suspension of duty to file reports under Section 13 and 15(d) of the Act Section 12 (g). | 1 | 2010-07-30 |
5/A | Amendment to a previously filed Form 5 | 1 | 2007-03-02 |
5 | Annual statement of changes in beneficial ownership of securities | 1 | 2007-02-13 |
NT 10-Q | Notification that form 10-Q will be submitted late | 3 | 2006-04-28 |
UPLOAD | Correspondence from the SEC to the Filer | 1 | 2006-04-26 |
UPLOAD | Correspondence from the SEC to the Filer | 1 | 2006-04-26 |
8-K | Report of unscheduled material events or corporate changes. | 4 | 2006-04-12 |
UPLOAD | Correspondence from the SEC to the Filer | 1 | 2006-04-10 |
UPLOAD | Correspondence from the SEC to the Filer | 1 | 2006-04-10 |